Angelman syndrome antisense treatment

dc.creator	Dindot, Scott Victor
dc.date.accessioned	2022-01-11T19:17:22Z
dc.date.available	2022-01-11T19:17:22Z
dc.date.issued	2021-12-14T00:00:00Z
dc.identifier.uri	https://hdl.handle.net/1969.1/195043
dc.description.abstract	Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5'-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.	en
dc.language	EN
dc.publisher	United States. Patent and Trademark Office
dc.rights	Public Domain (No copyright - United States)	en
dc.rights.uri	http://rightsstatements.org/vocab/NoC-US/1.0/
dc.title	Angelman syndrome antisense treatment	en
dc.type	Utility patent	en
dc.format.digitalOrigin	reformatted digital	en
dc.description.country	US
dc.contributor.assignee	Texas A&M University System
dc.identifier.patentapplicationnumber	16/767916
dc.date.filed	2018-11-30T00:00:00Z
dc.publisher.digital	Texas A&M University. Libraries
dc.subject.cpcprimary	C12N 15/113
dc.subject.cpcprimary	C07H 21/04
dc.subject.cpcprimary	C12N 2320/30
dc.subject.cpcprimary	C12N 2310/113
dc.subject.cpcprimary	C12N 2310/346
dc.subject.cpcprimary	C12N 2310/341